COVIVAXX is a new vaccine candidate to protect against COVID-19. Developed by the Serum Institute of India Pvt. LTD (SIIPL), the globally leading vaccine manufacturer, VPM coordinates the clinical development in Europe. A phase I/II trial is currently ongoing in Australia to assess the safety and immunogenicity of COVIVAXX in humans. A pivotal phase III trial is planned to be conducted in Europe and India in the first half of 2021. Click here to read more.
Milestone achieved: Initiation of all clinical centers for a large African trial against tuberculosis in neonates completed
We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the completed initiation of all clinical trial centers. Read more!
We are happy to announce that Vakzine Projekt Management GmbH (VPM) together with Grit Overseas Pte. Ltd. in Singapore successfully notified a COVID-19 rapid antigen test to the German Institute for Pharmaceuticals and Medical Products (BfArM).
"The DiagnoSure SARS-CoV-2 Antigen Rapid Test is now available and will get reimbursed by the health insurance upon prescription by a doctor.", says Oorvahsk F. Dastoor, Managing Director of Grit Overseas.
The test detects the viral N-protein and is therefore applicable for all virus mutants independent of mutations in their spike protein. This allows a reliable and fast detection of SARS-CoV-2 for everyone.
"We are proud to be involved to make an additional rapid antigen test accessible to the public in this COVID-19 pandemic", says Dr. Leander Grode, Managing Director of VPM. This is the first medicinal product VPM was involved in.
First clinical center in South Africa initiated for a Pan-African phase III trial against tuberculosis
Vakzine Projekt Management GmbH (VPM) announces that the first clinical center in South Africa has been initiated in a large phase III trial (priMe) to assess the efficacy and safety of the novel TB vaccine – VPM1002 - in comparison with BCG in healthy newborn infants. The clinical centers in Tanzania, Uganda and Gabon will follow in the next weeks.
"MHH testet Corona-Impfstoff – besser als Biontech & Co.?" Read more!
Vakzine Projekt Management GmbH (VPM) announces that the first participant has been enrolled in a large phase III trial to assess the efficacy and safety of the novel TB vaccine – VPM1002 - in comparison with BCG in healthy newborn infants. Read more!
Following the successful completion of phase II part of the Tdap study (tetanus, diphtheria and pertussis) Tadeus, phase III part will commence this week, which will include adults, adolescents and children to test the safety and immunogenicity of this vaccine. Read more!